---
layout: default
title: Ganirelix
parent: Model Prediction Only (L5)
nav_order: 426
evidence_level: L5
indication_count: 10
last_modified_at: 2026-10-28
monitor_inn: "GANIRELIX"
predicted_indications: ["hypertrichosis (disease)", "Ambras type hypertrichosis universalis congenita", "malformation syndrome with odontal and/or periodontal component", "syndrome with a Dandy-Walker malformation as major feature", "isolated genetic hair shaft abnormality", "familial male-limited precocious puberty", "persistent fetal circulation syndrome", "aromatase excess syndrome", "centra precocious puberty 1", "familial isolated trichomegaly"]
description: "Ganirelix: predicted new indication Hypertrichosis (disease) (evidence level L5). Approved use: Not recorded in the local data"
---

# Ganirelix
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **10** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist" markdown="1">

## Pharmacist Assessment Report

</div>

## Ganirelix: Hypertrichosis (disease)
{: .text-alpha }

## One-Sentence Summary

Ganirelix is a GnRH receptor antagonist used to prevent premature ovulation in women undergoing ovarian stimulation during fertility treatment.
The TxGNN model predicts it may be effective for **hypertrichosis**, but **no clinical trials and no publications** were found to support this direction.
This is a model-only prediction, and the mechanistic rationale is weak.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Hypertrichosis (disease) |
| TxGNN Prediction Score | 0.9998 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (valid licenses: 1 of 1) |
| Number of DINs | 1 (valid: 1) |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Ganirelix blocks the GnRH receptor (GNRHR) in the pituitary. This suppresses the release of LH and FSH and, downstream, the production of gonadal sex steroids. Its established use is short-term suppression of premature LH surges during ovarian stimulation.

The link to hypertrichosis is weak. Hypertrichosis is excess hair growth that is not driven by sex steroids, unlike hirsutism, so blocking the pituitary-gonadal axis has no clear rationale here. The high score comes from the TxGNN model (deep learning) and most likely reflects similarities the model learned between related hair phenotypes, not biological evidence or a real pharmacological connection.

Other top-ranked predictions are similarly weak. These include Ambras-type hypertrichosis, structural malformation syndromes, genetic hair shaft abnormalities, and trichomegaly. The more biologically adjacent candidates are:

- **Central precocious puberty**: the most plausible, since it involves early activation of the same axis. However, GnRH agonists are the standard of care, and ganirelix is a short-acting product, so its suitability for chronic suppression is uncertain.
- **Familial male-limited precocious puberty**: it is driven by activating LHCGR mutations downstream of the pituitary, so a GnRH antagonist alone would not be expected to work.
- **Aromatase excess syndrome**: ganirelix would not address peripheral aromatase activity, and aromatase inhibitors are more direct.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## Canada Market Information

| DIN | Product Name | Dosage Form | Approved Indication |
|---------|------|------|-----------|
| 02245641 | ORGALUTRAN | Not listed | Not listed |

---

## Safety Considerations

- **Drug Interactions**: Seven interaction records were compiled. Six are rated Moderate and involve other agents acting on the reproductive hormone axis:
  - Gonadorelin
  - Chorionic gonadotropin (human)
  - Menotropins
  - Triptorelin
  - Follitropin
  - Urofollitropin

  The seventh is a pharmacology record confirming that ganirelix acts on the GnRH₁ receptor.

Please refer to the package insert for warnings and contraindications.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The prediction rests only on a score from the TxGNN model (deep learning), which may reflect similarities the model learned between related diseases, not biological evidence. There are no trials or publications, and the mechanism does not support a role in hypertrichosis. The condition is not sex-steroid-driven, so GnRH antagonism has no clear rationale.

**To proceed, the following is needed:**
- A package insert review from Health Canada covering warnings, contraindications, dosage form, and approved indication
- Detailed mechanism-of-action data from DrugBank
- A literature and trial search for the more plausible hormone-axis indications, with central precocious puberty as the priority, compared against the established standards of care
- A route and formulation assessment, since ganirelix is a short-acting product intended for assisted reproduction
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

